Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards patient-centered healthcare: a scoping review of soft skills training in medical schools.

BMC medical education·2026
Same author

Global performance of predictive models for dengue severity, hospitalization and mortality: A systematic review and meta-analysis of 146 studies.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Influence of blood-brain barrier and intestinal barrier on microglial phenotypes: a perspective of clinical and prognostic implications.

Frontiers in immunology·2026
Same author

Clinical Characteristics, Infection Profiles, and Hospital Outcomes of Intensive Care Unit Patients Undergoing Antimicrobial Therapy with Ceftolozane/Tazobactam: A Multicentric Retrospective Analysis.

Antibiotics (Basel, Switzerland)·2026
Same author

Heme-induced ITAM signaling exacerbates malaria-associated neuropathogenesis through activation of platelet mTOR.

Blood·2026
Same author

Pharmacodynamic profile of Hexadimethrine Bromide-induced eosinophilia - Roles of pro-eosinophilic mediators.

European journal of pharmacology·2026

Related Experiment Video

Updated: May 15, 2026

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging
09:04

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging

Published on: June 8, 2017

Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria.

Patricia A Reis1, Vanessa Estato, Tathiany I da Silva

  • 1Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil. reispa@gmail.com

Plos Pathogens
|January 10, 2013
PubMed
Summary
This summary is machine-generated.

Statins, a class of cholesterol-lowering drugs, show promise in preventing cognitive impairment following severe malaria (CM) and sepsis. This study found statin treatment protected against neuroinflammation and cognitive deficits in mouse models.

More Related Videos

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice
12:48

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice

Published on: January 2, 2013

Related Experiment Videos

Last Updated: May 15, 2026

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging
09:04

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging

Published on: June 8, 2017

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice
12:48

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice

Published on: January 2, 2013

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Cerebral malaria (CM) is a severe Plasmodium falciparum complication causing persistent cognitive impairment in survivors.
  • Current therapeutic interventions for CM-related cognitive sequelae are lacking.
  • Statins possess immunomodulatory properties beyond cholesterol synthesis inhibition.

Purpose of the Study:

  • To investigate the neuroprotective potential of statins in preventing cognitive impairment in a murine model of cerebral malaria.
  • To assess the effects of statins on neuroinflammation and blood-brain barrier integrity in experimental CM.

Main Methods:

  • A murine model of cerebral malaria (Plasmodium berghei ANKA infection) was utilized.
  • Mice were treated with chloroquine alone or in combination with lovastatin.
  • Cognitive function was assessed using a battery of tests; neuroinflammation and vascular changes were evaluated via molecular and imaging techniques.

Main Results:

  • Lovastatin treatment reversed CM-induced decreases in functional capillary density and leukocyte-endothelial interactions.
  • Statins reduced brain edema, ICAM-1, CD11b mRNA, oxidative stress, and inflammatory mediators in infected mice.
  • Cognitive dysfunction was prevented in CM mice treated with chloroquine and lovastatin, unlike those treated with chloroquine alone.
  • Similar neuroprotective effects were observed in experimental bacterial sepsis.

Conclusions:

  • Statin treatment effectively prevents neuroinflammation and blood-brain barrier dysfunction in experimental cerebral malaria.
  • Statins demonstrate neuroprotective effects in severe infectious syndromes, including CM.
  • Statins may serve as valuable adjuvant therapy to prevent cognitive impairment in patients recovering from CM.